: Investors are currently focused on its experimental epilepsy drug, Epidiolex.
: Identified as a high-potential stock for investors willing to weather early-stage volatility. Canopy Growth Corporation (CGC)
: A leader in cannabinoid-based prescription medicines.
: Received its license to cultivate in February 2015 and operates a 55,000 sq. ft. purpose-built facility.
: Developing proprietary product candidates to treat pain and inflammation.
: Its drug Sativex is already approved in 28 countries for multiple sclerosis.
The Best Pot Stocks of 2015: Top Picks for the Budding Industry